Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Current Assets (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Current Assets for 8 consecutive years, with $165.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 113.46% to $165.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $165.0 million, a 113.46% increase, with the full-year FY2024 number at $61.3 million, down 50.81% from a year prior.
  • Current Assets was $165.0 million for Q3 2025 at Whitehawk Therapeutics, down from $178.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $232.6 million in Q1 2025 to a low of $37.4 million in Q2 2021.
  • A 5-year average of $131.5 million and a median of $135.6 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 232.49% in 2022, then crashed 50.81% in 2024.
  • Whitehawk Therapeutics' Current Assets stood at $151.3 million in 2021, then rose by 19.01% to $180.0 million in 2022, then plummeted by 30.8% to $124.6 million in 2023, then plummeted by 50.81% to $61.3 million in 2024, then skyrocketed by 169.28% to $165.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Current Assets are $165.0 million (Q3 2025), $178.7 million (Q2 2025), and $232.6 million (Q1 2025).